Workshop "Stage IV gastric cancer"

11th NOVEMBER: CONGRESS

08.30 Welcome message from the Congress President: G Ercolani

08.45 Who is Oligometastatic GC patient?
CHAIRMAN:    AH Hölscher, P Mansfield

• according to OMEC Project  -  R van Hillegersberger
• according to AIO-FLOT 3 results? - SP Moenig

• according to Eastern literature?  -  HK Yang
• according to Prospective GIRCG Database?  -  GM Tiberio
• Oligometastic gastric cancer treatment: the new perspective according to JCOG - M Terashima

DISCUSSANT:    OA Prado Castro,  M Pera

10:00 Oligometastatic GC treatment
CHAIRMAN:    HJ Meyer, M Degiuli

• The REINASSANCE trial: work in progress - GO Thorsten  
• The dynamic impact of therapies on Oligometastatic GC: may target therapy, immunotherapy or a combination of them enlarge such category? - S Cascinu

11.00 Coffee break
 
11.00 The approach to Peritoneal carcinosis
CHAIRMAN:    P Kassab, F Roviello

• The Phantom of the Opera: Peritoneal Cytology. How to evaluate, treat and with which benefits  -  B Wijnhoven
• Bidirectionality is essential for treatment oligometastatic peritoneal carcinosis/ What could it be the future role of HIPEC / PIPAC?  -  D Marrelli
• Eastern experience on bidirectional treatment in oligometastatic gastric cancer - JBY So

DISCUSSANT:    PM Da Costa, LG Lourenco
 
13.00 Lunch
 
14.45   Heavily metastatic cancer treatment
CHAIRMAN:    D D’Ugo, M Di Bartolomeo

• The optimal oncological treatment based on tumour characteristics  -  D Melisi
• Conversion surgery: when is it worth it? Analyses of literature data  -  HH Hartgrink
• May immunotherapy change conversion strategies?  -  S Lonardi
• Pathological lymphatic regression and prognosis - M Vieth
• How to plan future reseach in the field of metastatic GC?  -  S Markar
• A Comprehensive PDX Gastric Cancer Collection: how to personalize oncological treatment? - S Giordano

DISCUSSANT:    R Langer, L Lara Santos
 
15.30 End stage disease: cure is not the same of attack; stay in defence
CHAIRMAN:    A Donini, P Schneider

• Palliative surgery: when should be considered?  -  M Nilsson
• Step by step in the foggy landscape: the new borders  -  P Morgagni
• End stage disease: cure is not the same of attack; stay in defence - Nutritional support  -  R Caccialanza
• Bioethical approach to end stage disease  -  S Patuzzo
• Better to say no: when stop treatments  -  M Maltoni

DISCUSSANT:    W Kielan, A Weston
 
17.00 Coffee break
 
17.20  Meeting of the Poorly Cohesive Working Group

• Summary of poorly cohesive gastric cancer studies published since the publication of the consensus paper and their importance for patient management -  R Langer
• Ongoing trials and future perspectives of research on PC Gastric Cancer: The surgeon  - S Moenig
• Ongoing trials and Future perspectives of research on PC Gastric Cancer: The medical oncologist - D Melisi 

CHAIRMAN:    G De Manzoni, H Grabsch, F Carneiro

Discussion 45’: A Tomezzoli - M Iglesias - F Renaud - L Saragoni - G De Manzoni - F Carneiro - R Langer - H Grabsch - M Bencivenga - M Pera - A Holscher - P Morgagni - S Giacopuzzi - S Moenig - D Melisi - R Rosati - C Molinari - F Berlth - D Liu - C Castelli

Next steps (summary/action points from the discussion and previous work) - H Grabsch

​
12th NOVEMBER: HOMEWORKS
 
09.00 The better you stage, the better you treat it
Chairman:    G Martinelli, L Saragoni

• The new frontiers of oncological treatments for Gastric Cancer: focus on FGFR pathway  -  A Quinzii
• Liquid biopsy and tumour profiling in Gastric Cancer  -  C Molinari
• Gastric Cancer Therapies: how to improve patients’ performance status in clinical practice  -  M Salati
• The role of HIPEC in treatment of peritoneal metastases  -  M Framarini
• Bidirectional treatments for oligometastatic synchronous peritoneal carcinosis   -  F Casella

Discussion
 
10.30 Coffee break
 
11.00 Conversion and quality of care
Chairman:    G Mura,  M Bencivenga

• The conversion surgery registry: prospective molecular data collection  -  C Milandri
• The GEA (Gastro-Esophageal Annotated platform) experience: a successful multicentre clinical translational study -  S Corso
• How to stage regression? The radiologist experience in the prospective GIRCG study  -  G Bagnacci
• Quality of care: not only surgery  -  L Marano
• Palliation of symptoms and pain control in end-stage disease  -  V Rossi
• The strict relation between experts and patients' association.  -  C Santangelo

Discussion

13.00 Don't believe anything you have heard! (Take home messages from the Experts' Workshop)  - 
P Morgagni, G De Manzoni, F Roviello, D Marrelli, L Saragoni
 
13.30 Conclusion